Drugmaker pulls painkillers from US market over heart risks

Nov 19, 2010

Drugmaker Xanodyne Pharmaceuticals Inc. agreed Friday to pull two of its painkillers, Darvon and Darvocet, from the US market over heart risk concerns, the US Food and Drug Administration said.

Similar withdrawals from the market of the drug also known as propoxyphene were recommended in Europe in 2009 and are already under way.

"The FDA sought market withdrawal of propoxyphene after receiving new clinical data showing that the drug puts patients at risk of potentially serious or even fatal ," the agency said.

"As a result of these data, combined with other information, including new epidemiological data, the agency concluded that the risks of the medication outweigh the benefits."

Generic manufacturers of the medication were also notified of Xanodyne's decision and urged to do the same, the FDA said.

The European Medicines Agency recommended in 2009 that "marketing authorizations for propoxyphene be withdrawn across the European Union. A phased withdrawal of propoxyphene is underway," the FDA noted.

Propoxyphene, an opioid used to treat mild to moderate pain, has been on the US market since it was first approved by the FDA in 1957.

Explore further: Bangladesh jails three over drug scam that killed hundreds of children (Update)

add to favorites email to friend print save as pdf

Related Stories

FDA orders overdose warnings for Darvocet

Jul 07, 2009

(AP) -- The government is letting the painkillers Darvocet, Darvon and their generic cousins stay on the market but ordered stronger warnings against deadly overdoses on Tuesday.

FDA relents from midodrine withdrawal plan

Sep 06, 2010

(AP) -- Federal regulators have backed off a plan to remove a Shire PLC low blood-pressure treatment from the market after warning in August that the drug has not been proven effective.

FDA rejects new obesity drug Qnexa

Oct 30, 2010

The US Food and Drug Administration has rejected a marketing request by Vivus for its new obesity treatment called Qnexa, because it considers it a health risk, the California-based biotech firm said in a statement.

FDA cracks down on hydrocone products

Sep 29, 2007

The U.S. Food and Drug Administration says it will start taking enforcement action against companies marketing unapproved hydrocodone products.

Recommended for you

Supermaterial gives rejected drugs a new chance

4 hours ago

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Chace_Schutte
5 / 5 (1) Nov 19, 2010
I'm so happy I read this 15 mins after it was published, My doc prescribed me these and I have been reluctant to take any kind of pills because I prefer vaporizing marijuana. I have taken them but I'm not going to anymore : P THANK YOU PHYSORG!